Private Harbour Investment Management & Counsel LLC cut its holdings in Bristol-Myers Squibb Company (NYSE:BMY) by 4.1% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 22,476 shares of the biopharmaceutical company’s stock after selling 950 shares during the quarter. Private Harbour Investment Management & Counsel LLC’s holdings in Bristol-Myers Squibb were worth $1,252,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the company. Brookstone Capital Management boosted its position in Bristol-Myers Squibb by 17.1% during the second quarter. Brookstone Capital Management now owns 10,973 shares of the biopharmaceutical company’s stock worth $611,000 after acquiring an additional 1,603 shares during the last quarter. Buckingham Asset Management LLC boosted its position in Bristol-Myers Squibb by 8.7% during the second quarter. Buckingham Asset Management LLC now owns 17,508 shares of the biopharmaceutical company’s stock worth $976,000 after acquiring an additional 1,401 shares during the last quarter. High Pointe Capital Management LLC boosted its position in Bristol-Myers Squibb by 74.4% during the second quarter. High Pointe Capital Management LLC now owns 26,700 shares of the biopharmaceutical company’s stock worth $1,488,000 after acquiring an additional 11,390 shares during the last quarter. Tobam boosted its position in Bristol-Myers Squibb by 38.1% during the second quarter. Tobam now owns 1,096,089 shares of the biopharmaceutical company’s stock worth $61,074,000 after acquiring an additional 302,375 shares during the last quarter. Finally, Pacer Advisors Inc. boosted its position in Bristol-Myers Squibb by 6.3% during the second quarter. Pacer Advisors Inc. now owns 37,947 shares of the biopharmaceutical company’s stock worth $2,114,000 after acquiring an additional 2,250 shares during the last quarter. Institutional investors and hedge funds own 69.51% of the company’s stock.

Bristol-Myers Squibb Company (NYSE:BMY) opened at $60.86 on Monday. Bristol-Myers Squibb Company has a one year low of $46.01 and a one year high of $66.10. The company has a quick ratio of 1.46, a current ratio of 1.59 and a debt-to-equity ratio of 0.47. The company has a market cap of $99,609.57, a price-to-earnings ratio of 20.56, a PEG ratio of 2.40 and a beta of 1.18.

Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 EPS for the quarter, missing the Zacks’ consensus estimate of $0.77 by ($0.02). Bristol-Myers Squibb had a net margin of 20.56% and a return on equity of 32.41%. The business had revenue of $5.25 billion during the quarter, compared to analysts’ expectations of $5.20 billion. During the same period in the prior year, the business posted $0.77 EPS. The business’s revenue was up 6.7% on a year-over-year basis. sell-side analysts forecast that Bristol-Myers Squibb Company will post 2.99 earnings per share for the current year.

The company also recently declared a quarterly dividend, which was paid on Wednesday, November 1st. Investors of record on Friday, October 6th were issued a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a yield of 2.56%. The ex-dividend date of this dividend was Thursday, October 5th. Bristol-Myers Squibb’s payout ratio is 61.42%.

WARNING: “Private Harbour Investment Management & Counsel LLC Lowers Stake in Bristol-Myers Squibb Company (BMY)” was first posted by Watch List News and is owned by of Watch List News. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.watchlistnews.com/private-harbour-investment-management-counsel-llc-lowers-stake-in-bristol-myers-squibb-company-bmy/1699315.html.

A number of analysts recently issued reports on BMY shares. UBS AG restated a “buy” rating and set a $72.00 target price (up previously from $62.00) on shares of Bristol-Myers Squibb in a research report on Friday, October 6th. Vetr upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $67.92 target price on the stock in a research report on Monday, October 9th. Zacks Investment Research lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Thursday, November 2nd. BMO Capital Markets restated a “sell” rating and set a $49.00 target price on shares of Bristol-Myers Squibb in a research report on Monday, September 4th. Finally, Citigroup Inc. raised their target price on shares of Bristol-Myers Squibb to $72.00 and gave the stock a “buy” rating in a research report on Wednesday, October 18th. One investment analyst has rated the stock with a sell rating, ten have given a hold rating and eleven have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $64.93.

In related news, SVP Joseph C. Caldarella sold 9,340 shares of the firm’s stock in a transaction on Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total transaction of $560,400.00. Following the completion of the sale, the senior vice president now directly owns 46,297 shares of the company’s stock, valued at approximately $2,777,820. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 0.23% of the stock is currently owned by company insiders.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with Analyst Ratings Network's FREE daily email newsletter.